This biotech company is rolling the dice with a planned regulatory submission.Sometimes, everything can seem to be going your way. And then the wheels fall off. That's the situation Summit Therapeutics (SMMT +0.06%) finds itself in.Shares of the clinical-stage biotech company skyrocketed 584% last year. The stock more than doubled again by late April 2025. However, Summit subsequently gave up all of its year-to-date gains and then some. What happened? Summit's lead pipeline candidate, ivonescimab, failed to ...